Allos Therapeutics Added to NASDAQ Biotech Index
20 Novembro 2006 - 11:00AM
PR Newswire (US)
WESTMINSTER, Colo., Nov. 20 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) today announced that the Company
has been selected for inclusion in the NASDAQ Biotechnology Index
(NBI), effective as of the market's open today, November 20, 2006.
"We are very pleased to be included in the NASDAQ Biotechnology
Index and believe that our selection is further recognition of our
consistent progress and recent achievements" said Paul L. Berns,
President and Chief Executive Officer. "We look forward to
continuing to execute on our strategy to deliver innovative
medicines that enhance and extend the lives of cancer patients."
The NBI was launched in 1993 and includes biotechnology and
pharmaceutical companies listed on the NASDAQ National Market that
meet minimum requirements for market value, average daily share
volume and seasoning as a public company. The NBI is ranked on a
semi-annual basis in May and November and serves as the basis for
the iShares Nasdaq Biotechnology Index Fund (AMEX: IBB). For more
information about the Nasdaq Biotechnology Index, including
eligibility criteria, visit http://www.nasdaq.com/. About Allos
Therapeutics, Inc. Allos Therapeutics, Inc. (ALTH) is a
biopharmaceutical company focused on the development and
commercialization of small molecule therapeutics for the treatment
of cancer. The Company has two product candidates in late-stage
clinical development: EFAPROXYN (efaproxiral), a radiation
sensitizer currently under evaluation in a pivotal Phase 3 trial in
women with brain metastases originating from breast cancer, and PDX
(pralatrexate), a novel, next generation antifolate currently under
evaluation in a pivotal Phase 2 trial in patients with relapsed or
refractory peripheral T-cell lymphoma. The Company is also
evaluating RH1, a targeted chemotherapeutic agent, in a Phase 1
trial in patients with advanced solid tumors. For additional
information, please visit the Company's website at
http://www.allos.com/. DATASOURCE: Allos Therapeutics, Inc.
CONTACT: Jennifer Neiman, Manager, Corporate Communications of
Allos Therapeutics, Inc., +1-720-540-5227, Web site:
http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024
Notícias em tempo-real sobre Allos Therapeutics, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Allos Therapeutics (MM)